Eculizumab Therapy for Chronic Complement-Mediated Injury in Kidney Transplantation
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
This study is designed to assess the effectiveness of eculizumab in recipients of kidney
transplantation with donor-specific antibodies (DSA) and worsening kidney function and to
assess if eculizumab improves endothelial cell injury in the kidney.
The investigators hypothesize that complement inhibition with eculizumab will reduce
allograft injury, resulting from less complement-mediated injury of endothelial cells and
less endothelial cell activation.